Candriam S.C.A. Crinetics Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $16.8 Billion
- Q2 2025
A detailed history of Candriam S.C.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 693,869 shares of CRNX stock, worth $18.6 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
693,869
Previous 488,911
41.92%
Holding current value
$18.6 Million
Previous $16.4 Million
21.69%
% of portfolio
0.12%
Previous 0.11%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
232Shares Held
86.7MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$250 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$185 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$168 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$167 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$137 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.44B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...